Congress opens Medicare to digital health products with minimal price guardrails

What it does

This bill adds prescription digital therapeutics—software-based medical products cleared by the FDA—to Medicare and Medicaid coverage starting January 1, 2026. The Secretary of Health and Human Services must establish a payment method for manufacturers within one year, create billing codes within two years, and require manufacturers to report pricing and usage data annually, with penalties up to $10,000 per day for false reporting.

Why we flagged it

The bill's core function is to add a new category of FDA-cleared digital therapeutics to Medicare and Medicaid coverage, establishing payment and coding infrastructure. It is primarily a coverage and reimbursement mechanism, not a deregulation or subsidy carve-out, though it does create favorable conditions for a nascent industry.

What the text implies

• The bill does not establish a reference pricing benchmark or cost-effectiveness threshold before coverage, unlike traditional drugs. Manufacturers report 'actual list charge' and private-payor rates, but the Secretary has broad discretion to set payment 'as determined appropriate'—potentially allowing high initial prices to anchor reimbursement.
• Manufacturer reporting requirements (pricing, volume, user counts) are subject to confidentiality protections identical to drug pricing data under section 1927, which may limit public transparency and price comparison.
• The bill covers digital therapeutics that are 'exempt from section 502' under FDA regulations—a regulatory category that may include lower-scrutiny products, yet they receive the same Medicare/Medicaid coverage pathway as fully approved devices.
• No explicit exclusion for duplicative or low-efficacy products; once FDA-cleared, a digital therapeutic is eligible for coverage, shifting cost-benefit analysis to the Secretary without statutory guardrails.
• The one-time or periodic payment structure is undefined; manufacturers could negotiate ongoing subscription-style payments, creating recurring taxpayer obligations for products that may have limited clinical evidence.

Who it affects

Patients gain access to FDA-cleared digital treatments through Medicare and Medicaid, potentially lowering out-of-pocket costs and expanding treatment options. However, the bill creates a new payment pathway with minimal price controls, manufacturer reporting requirements that may be weak, and no explicit cost-containment mechanisms—risking higher taxpayer costs and manufacturer pricing power without clear public safeguards.

Who stands to gain

• digital therapeutics manufacturers
• software-based medical device companies
• FDA-cleared digital health startups

Named in the bill

Medicare, Medicaid, FDA (Food and Drug Administration), HHS Secretary, HCPCS (Healthcare Common Procedure Coding System), Social Security Act, Federal Food, Drug, and Cosmetic Act, LGND (Ligand Pharmaceuticals), ALGN (Align Technology), GEN (Gen Digital), VTRS (Viatris)

Where it stands

4 cosponsors: 2 Democrats, 2 Republicans.

• May 8, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 8, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $160,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Shelley Capito, the sponsor, reported $2,021,591 in PAC receipts in the 2026 cycle.

• Academy of Managed Care Pharmacy — $160,000 on 2 filings

Lobbying Disclosure Act filings through Jul 19, 2026. A filing shows who paid to lobby on a bill it names, not what changed.